Laekna Limited   Report issue

For profit Phase 2
Founded: Shanghai China (2016)

Organization Overview

First Clinical Trial
2019
NCT03843918
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Laekna Limited | Laekna LLC | Laekna Therapeutics

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Ovarian Epithelial (Phase 2)

Ovarian Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 7